Tumor‐intrinsic CD21 expression impacts the response of B‐cell malignancy cells to CD19‐CAR‐T cells
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Leukocyte Biology"
DOI: 10.1002/jlb.5ma0122-474r
Abstract: CD19‐chimeric antigen receptor (CAR)‐based T‐cell therapy has produced promising clinical responses in patients with relapsed or refractory B‐cell malignancies. However, a significant portion of patients with mature B cell‐derived malignancies, including chronic lymphocytic leukemia (CLL)… read more here.
Keywords: cell; cd19 car; cells cd19; car ... See more keywords
A novel fourth generation of CAR-T cells: CD19 CAR-T cells engineered to express membrane-bound interleukin-15 and CXCR5 for the treatment of lymphoma
Sign Up to like & getrecommendations! Published in 2025 at "Clinical and Experimental Medicine"
DOI: 10.1007/s10238-025-01860-3
Abstract: The efficacy of CD19 CAR-T cells in B-cell lymphoma patients is not as good as that in B-cell acute lymphoblastic leukemia (B-ALL) patients. This might be attributed to the intricate tumor microenvironment of B-cell lymphoma,… read more here.
Keywords: cxcr5; car; tumor; car cells ... See more keywords
CD19 CAR T Cells
Sign Up to like & getrecommendations! Published in 2017 at "Cell"
DOI: 10.1016/j.cell.2017.12.002
Abstract: CARs are synthetic receptors that reprogram immune cells for therapeutic purposes. They comprise three canonical domains for antigen recognition, T cell activation, and costimulation. The CAR cDNA is genetically integrated in the T cell genome.… read more here.
Keywords: car cells; cell; car; cd19 car ... See more keywords
Beyond CD19 CAR-T cells in lymphoma.
Sign Up to like & getrecommendations! Published in 2021 at "Current opinion in immunology"
DOI: 10.1016/j.coi.2021.09.009
Abstract: Adoptive transfer of CD19-specific chimeric antigen receptor T-cells (CAR-T cells) has transformed the treatment paradigm of relapsed/refractory (R/R) CD19 B-cell malignancies, dramatically improving remission rates and cures in patients with chemo-refractory disease. However, the applicability… read more here.
Keywords: cd19; beyond cd19; car cells; cell ... See more keywords
Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro.
Sign Up to like & getrecommendations! Published in 2020 at "Immunology letters"
DOI: 10.1016/j.imlet.2020.04.005
Abstract: In spite of impressive results in the treatment of acute lymphoblastic B cell leukemia (B-ALL) with chimeric antigen receptor (CAR) T cells, the clinical outcome of some hematological cancers like follicular lymphoma (FL) and chronic… read more here.
Keywords: a2ar; anti cd19; pharmacological targeting; car cells ... See more keywords
Prophylactic tocilizumab before CD3/4-1bb anti-CD19 car-T cell infusion decreases incidence of severe crs without increased risk of neurotoxicity
Sign Up to like & getrecommendations! Published in 2020 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2020.03.483
Abstract: Background & Aim Anti-CD19 CAR-T cells have demonstrated activity against relapsed/refractory lymphomas. Cytokine release syndrome (CRS) and CAR-T related encephalopathy syndrome (CRES) are well-known complications of CAR-T cell therapy. Tocilizumab, a humanized monoclonal antibody targeting… read more here.
Keywords: car cell; crs; anti cd19; car ... See more keywords
EVALUATION OF ANTI-CD19 CAR-T CELL PERSISTENCE AND EFFICACY USING A DEVELOPED MULTIPARAMETRIC FLOW CYTOMETRY AND QPCR TRACKING PLATFORM FOR PRECLINICAL AND CLINICAL STUDIES
Sign Up to like & getrecommendations! Published in 2021 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2021.02.043
Abstract: Background Anti-CD19 chimeric antigen receptor (CAR)-expressing T cells have shown remarkable remission rates in acute B cell leukemias. It has been reported that anti-CD19 CAR-T cells sustain complete remission of leukemia even when their numbers… read more here.
Keywords: flow cytometry; anti cd19; cell; cd19 car ... See more keywords
Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children
Sign Up to like & getrecommendations! Published in 2020 at "Leukemia"
DOI: 10.1038/s41375-020-0831-z
Abstract: Despite high remission rates after CD19 CAR T-cell therapy in patients with refractory or relapsed B acute lymphoblastic leukemia (r/r B-ALL), relapses were commonly observed [1–4]. To improve long-term disease-free survival (DFS), our and other… read more here.
Keywords: cd19; tp53 mutation; therapy; car ... See more keywords
Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion
Sign Up to like & getrecommendations! Published in 2022 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-021-01554-w
Abstract: TO THE EDITOR: Acute lymphoblastic leukemia (ALL) is a clinically and genetically heterogeneous hematopoietic malignancy, and 75% of ALL cases in adults are of B-cell lineage [1]. The Ikaros protein plays a vital role in… read more here.
Keywords: cd19 car; treatment; car cell; cell ... See more keywords
Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2020.1729735
Abstract: ABSTRACT Introduction: The success of CD19 chimeric antigen receptor (CAR)-T cell therapy for treatment of CD19 positive malignancies has led to the FDA approval of two CD19 CAR-T cell products, tisagenlecleucel and axicabtagene ciloleucel, and… read more here.
Keywords: car cell; car; neurotoxicity; cd19 car ... See more keywords
NCMP-17. Clinical Presentation, Management and Outcome of Tumor inflammation-associated neurotoxicity (TIAN) in CNS lymphoma treated with CD19-CAR T-cell therapy
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.1247
Abstract: Tumor inflammation-associated neurotoxicity (TIAN) was recently proposed as a unique complication of immunotherapy in brain tumor patients. Here, we report a first comprehensive characterization of TIAN in CNS lymphoma (CNSL) patients treated with CD19-directed chimeric… read more here.
Keywords: tumor; tumor inflammation; cd19 car; associated neurotoxicity ... See more keywords